Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Go back to Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™| Otter Lake Resources, Inc. New (NASDAQ: OTLK) | Delayed: 0.68 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.68 | 52 Week High | $0.03 | |||
| Open | $0.70 | 52 Week Low | $0.01 | |||
| Day High | $0.71 | P/E | N/A | |||
| Day Low | $0.68 | EPS | $0.00 | |||
| Volume | 2,254,554 | |||||
